La catena delle opzioni mostra i dati chiave delle opzioni azionarie di NexPoint Residential a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per NexPoint Residential..

NexPoint Residential (NYSE:NXRT) Azioni, Catena delle Opzioni

NexPoint Residential

NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.

NexPoint Residential Trust, Inc. Common Stock

NexPoint Residential Trust Inc

WIIM

GE Aerospace shares are trading lower. The company reported Q3 financial results.

News

GPRK

GeoPark Receives Approval From The Argentinian Securities Regulator To Issue Up To $500M In Debt Securities Over Next Five Years

Keybanc analyst Sophie Karp downgrades Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Overweight to Sector Weight.

Downgrades

Analyst Ratings

Keybanc Downgrades Duke Energy to Sector Weight

Deutsche Bank analyst Koosh Patel maintains AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Buy and raises the price target from $110 to $115.

Price Target

Deutsche Bank Maintains Buy on AerCap Holdings, Raises Price Target to $115

LXEO

Lexeo Therapeutics Says Interim Data From Ongoing Phase 1/2 Trial Of LX1001 Have Been Selected As Late-breaking Oral Presentation At CTAD Conference

Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.70 by 7.65 percent. This is a 5.17 percent increase over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $4.952 billion which missed the analyst consensus estimate of $5.048 billion by 1.89 percent. This is a 3.51 percent decrease over sales of $5.132 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

CORRECTION: Kimberly-Clark Q3 2024 Adj. EPS $1.83 Beats $1.70 Estimate, Sales $4.952B Miss $5.048B Estimate

Keybanc analyst Jackson Ader initiates coverage on Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Overweight rating and announces Price Target of $40.

Initiation

ZETA

Keybanc Initiates Coverage On Zeta Global Holdings with Overweight Rating, Announces Price Target of $40

Deutsche Bank analyst Hillary Cacanando maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $125 to $160.

FTAI

Deutsche Bank Maintains Buy on FTAI Aviation, Raises Price Target to $160

Biogen presentations include a late breaking oral presentation highlighting the conclusive data from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN).&nbsp;

BIIB

Biogen Plans To Present Variety Of New Data From Its Felzartamab Clinical Development Program At Kidney Week 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Organon will release its third quarter 2024 financial results on Oct. 31. The company's stock fell around 12% over the past month and has a <a href="https://www.benzinga.com/quote/OGN">52-week low of $10.84</a>.</li>
<li>RSI Value: 28.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OGN Price Action: Shares of Organon fell 0.9% to close at $17.45 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">latest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png" alt="" class="wp-image-607146" style="width:757px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></figure>
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)&nbsp;</h3>
<ul>
<li>On Oct. 21, Arcutis Canada announced Health Canada approval of ZORYVE&#xAE; Foam to treat seborrheic dermatitis in individuals 9 years of age and older. Dr. Melinda Gooderham, medical director at the SKiN Centre for Dermatology and a principal Canadian investigator in the pivotal Phase 3 STRATUM trial said, &#8220;The approval of ZORYVE foam by Health Canada is a significant development in the management of this condition. Clinical trial data show close to 80% of patients achieving treatment success at week 8 and rapid itch relief in as little as 48 hours.&#8221; The company's stock fell around 14% over the past five days and has a 52-week low of $1.76.</li>
<li>RSI Value: 28.13</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics fell 4.7% to close at $8.31 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">trend in ARQT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png" alt="" class="wp-image-606848" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>TransMedics Group will release financial results for the third quarter after market close on Monday, Oct. 28. The company's shares fell around 22% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MGRX">low of $36.42</a>.</li>
<li>RSI Value: 29.60</li>
<li>TMDX Price Action: Shares of TransMedics fell 1.7% to close at $124.48 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">breakout in TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png" alt="" class="wp-image-606851" style="width:702px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TMDX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.46 per share which met the analyst consensus estimate. This is a 9.8 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $485.862 million which beat the analyst consensus estimate of $482.156 million by 0.77 percent. This is a 6.54 percent increase over sales of $456.024 million the same period last year.

Old National Q3 2024 Adj. EPS $0.46, Inline, Sales $485.862M Beat $482.156M Estimate

2024 Financial Outlook
The following table and other sections of this news release contain forward-looking statements, which are based on the company&#39;s current expectations. Actual results may differ materially from those projected. It is the company&#39;s practice not to incorporate adjustments into its financial outlook for proposed or potential acquisitions, divestitures, ventures, pension risk transfer transactions or discretionary contributions, financing transactions, changes in law, or new accounting standards until such items have been consummated, enacted or adopted. For additional factors that may impact the company&#39;s actual results, refer to the &quot;Forward-Looking Statements&quot; section in this news release.
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
(in millions, except per share data)
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Current Update1
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
July 2024
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Net sales
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$71,250
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$70,500 - $71,500
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Business segment operating profit2
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$7,475
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$7,350 - $7,500
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Total FAS/CAS pension adjustment
</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,685
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,685
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Diluted earnings per share3
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$26.65
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$26.10 - $26.60
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Cash from operations
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$7,950
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$7,750 - $8,050
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Capital expenditures
</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,750
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,750
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Free cash flow2
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$6,200
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$6,000 - $6,300
</td>
</tr>
</tbody>
</table>

Guidance

Lockheed Martin Raises FY24 Outlook: GAAP EPS from $26.10-$26.60 to $26.65 vs $26.38 Est; Narrows Sales Guidance from $70.50B-$71.50B to $71.25B vs $71.05B Est

SNGX

Soligenix Says Hong Kong Patent Office Has Granted Patent Entitled 'Systems And Methods For Producing Synthetic Hypericin'

HYZN

Hyzon shares are trading higher after the company announced a purchase agreement for 12 hydrogen-powered refuse Fuel Cell Electric Vehicles with GreenWaste.

Contracts

Hyzon Enters Purchase Agreement With GreenWaste For 12 Fuel Cell Electric Vehicles

The transaction is expected to close in the&nbsp;fourth quarter&nbsp;of 2024, subject to customary closing conditions.

Asset Sales

MGNX

MacroGenics Enters Agreement With TerSera For Sale Of Global Rights Of MARGENZA; $40M To Be Paid At Closing And May Receive Additional Sales Milestone Payments Of Up To Of $35M

Biotech

General

MacroGenics Enters Agreement With TerSera Therapeutics, Under Which TerSera Will Acquire Global Rights To MARGENZA; TerSera To Pay MacroGenics $40M At Closing And MacroGenics May Receive Milestones Up To $35M

As previously announced on Oct. 2, 2024, the company&#39;s board authorized the repurchase of its common stock up to an additional $3.0 billion, increasing the total authorization for potential future common stock repurchases to $10.3 billion. The stock repurchase program does not have an expiration date and may be amended or terminated by the board of directors at any time. The amount of shares ultimately purchased and the timing of purchases are at the discretion of management and subject to compliance with applicable law and regulation.

Buybacks

Lockheed Martin Increased Stock Buyback Authorization By $3B To $10.30B On Oct. 2

Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.41 by 29.27 percent. The company reported quarterly sales of $87.555 million which beat the analyst consensus estimate of $78.147 million by 12.04 percent. This is a 3.73 percent increase over sales of $84.407 million the same period last year.

DCOM

Dime Community Bancshares Q3 2024 Adj. EPS $0.29 Misses $0.41 Estimate, Sales $87.555M Beat $78.147M Estimate

SIGA

SIGA Enters Exclusive License Agreement With Vanderbilt University To Obtain A License To A Portfolio Of Preclinical Fully Human Poxvirus Monoclonal Antibodies

Analyst Michael Lewis of Truist Financial maintained a Hold rating on NexPoint Residential (NXRT – Research Report), boosting the price target to $...

NexPoint Residential Trust: Hold Rating with Revised Price Target Amid Mixed Growth Projections

Dividend Champion, Contender, And Challenger Highlights: Week Of September 8

Leverage In Real Estate Investing

The State Of REITs: September 2024 Edition

Dividend Champion, Contender, And Challenger Highlights: Week Of September 22

SA Chart: Which sector will benefit the most from interest rate cuts?

TCW Global Real Estate Fund Q2 2024 Commentary

An October Surprise

Raymond James analyst Buck Horne upgraded NexPoint Residential (NXRT) to Outperform from Market Perform with a $50 price target The firm cites "res...

Comments

NexPoint Residential

NexPoint Residential (NXRT) Opzioni

NexPoint Residential (NYSE:NXRT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO